Grant: Undergraduate Student Research Awards (USRA)
University of Calgary
$6,000.00
Long term kidney outcomes in pediatric SLE
EF 2026-27
Résumé
"Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that can affect multiple organ systems such as the heart, lungs, skin, brain and kidneys. SLE is multifactorial due to environmental and underlying genetic factors. To date, data on long term outcomes of lupus have been mainly extrapolated from adult data. There have been some pediatric studies that have looked at long term outcome but were limited by either shorter duration follow-up or they did not include comparison of these outcomes between current recommended induction therapies. Our study aim is to assess long term kidney outcomes in pediatric lupus nephritis patients who received either cyclophosphamide or mycophenolate as initial induction therapy at different intervals. This will allow us to evaluate long-term kidney outcomes in the Canadian SLE pediatric population to determine whether these differ based on induction therapy used. Ultimately, these results may help us better tailor lupus nephritis management and potentially support prolonged preservation of kidney function.
We will conduct a retrospective cohort study using data collected between the years 2000 and 2025. Participants with a confirmed diagnosis of lupus nephritis (LN) class III or IV, based on kidney biopsy classification, will be included. Participants will be divided into two groups according to initial induction therapy received: a mycophenolate group and a cyclophosphamide group. Primary Outcomes: To evaluate long-term kidney outcome in both treatment groups based on progression to chronic kidney disease, development of end stage kidney disease and the need for renal replacement therapy (RRT).
"
Programme
Undergraduate Student Research Awards (USRA)
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
571671
Name
Shinyanbola Esther
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Long term kidney outcomes in pediatric SLE
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Calgary
Cihramount2
$6,000
Cihrequipment2
$0
Programname2
Undergraduate Student Research Awards (USRA)
Keyworddelim
Autoimmune Inflammatory Disease; Rgan Systems; Systemic Lupus Erythematosus
Abstract
"Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that can affect multiple organ systems such as the heart, lungs, skin, brain and kidneys. SLE is multifactorial due to environmental and underlying genetic factors. To date, data on long term outcomes of lupus have been mainly extrapolated from adult data. There have been some pediatric studies that have looked at long term outcome but were limited by either shorter duration follow-up or they did not include comparison of these outcomes between current recommended induction therapies. Our study aim is to assess long term kidney outcomes in pediatric lupus nephritis patients who received either cyclophosphamide or mycophenolate as initial induction therapy at different intervals. This will allow us to evaluate long-term kidney outcomes in the Canadian SLE pediatric population to determine whether these differ based on induction therapy used. Ultimately, these results may help us better tailor lupus nephritis management and potentially support prolonged preservation of kidney function.
We will conduct a retrospective cohort study using data collected between the years 2000 and 2025. Participants with a confirmed diagnosis of lupus nephritis (LN) class III or IV, based on kidney biopsy classification, will be included. Participants will be divided into two groups according to initial induction therapy received: a mycophenolate group and a cyclophosphamide group. Primary Outcomes: To evaluate long-term kidney outcome in both treatment groups based on progression to chronic kidney disease, development of end stage kidney disease and the need for renal replacement therapy (RRT).
"
Competitiondate
202605
Approvedterm2
0 yr 4 mths
Pinamesdelim
Shinyanbola, Esther
Approvedterm
0 an 4 mois
Cihrcontribution2
~ $6,000~ $0~